IRVINE, Calif., Feb. 2, 2012 /PRNewswire/ -- Syneron Medical Ltd. (NASDAQ: ELOS), www.syneron.com, the global leader in medical aesthetic products and technology, announces the launch of evolastin™– the industry's first energy-based dermal remodeling procedure that delivers controlled radio frequency energy directly to the deep dermis to stimulate the skin's natural production of collagen, elastin and hyaluronic acid in a single treatment.
A recent randomized and blinded clinical study published by leading dermatologists in the journal Archives of Dermatology proved the unique and dramatic impact of evolastin for patients seeking an alternative to address the loss of tautness and suppleness most common with age. "It is unprecedented to be able to achieve results as effective and consistent with a single energy-based procedure," comments Macrene Alexiades-Armenakas, M.D., Ph.D, F.A.A.D, board-certified dermatologist in New York City, Assistant Clinical Professor at Yale University School of Medicine and lead investigator of evolastin. "In a one-hundred patient multi-center study conducted using this procedure, we've seen continual textual, tone or elasticity in addition to volumetric improvements for up to eighteen months post procedure and patient satisfaction has been remarkably high and equally consistent."
Unlike traditional energy-based procedures that aim to reach the dermis through the surface, evolastin positions the entire energy directly at the base of the dermis using insulated microneedles that create a unique wound healing response. "evolastin is a major step forward in the field of facial aesthetics," says Amy Taub, M.D., board-certified dermatologist at Advanced Dermatology in Lincolnshire, Illinois and Assistant Clinical Professor at Northwestern University. "This procedure gives patients of all skin types results unlike any other energy-based procedure on the market – it addresses volume and lifts while improving skin quality and elasticity."evolastin™ is generally performed under local anesthetic in about an hour, allowing patients to drive home safely post-treatment and return to normal activities within 24 hours. Downtime is minimal with only minor redness, swelling or bruising for a few days.